Guardant Health Reaches New 52-Week High of $172.58

Guardant Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 172.58 on July 1, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 468.1%, significantly outpacing the S&P 500's growth of 20.74% during the same period. As a mid-cap player in the Pharmaceuticals & Biotechnology industry, Guardant Health has demonstrated strong financial metrics, including an impressive return on equity of 413.71%. Despite being a loss-making entity, the company has maintained a market capitalization of USD 11,098 million. Notably, the stock's price-to-book ratio stands at -111.76, and it carries a debt-to-equity ratio of -3.32, indicating a unique financial structure. The stock's previous 52-week low was recorded at USD 40.36, highlighting the substantial upward trajectory it has experienced. This new high reflects the company's evolving market position and the dynamics within the biotechnology sector.